Proteomics International Laboratories’ (ASX: PIQ) diabetic kidney illness tests ranked above current requirement of care

PIQ AGM Presentation

PIQ AGM Presentation

Proteomics International Laboratories’ (PIQ) PromarkerD test has been ranked by physicians above existing standard-of-care tests for anticipating diabetic kidney disease.

The arise from a PIQ study showing the clinical energy of the ProMarkerD test in anticipating diabetic kidney disease were released today in the PLOS ONE peer-reviewed journal.

The medical utility research study surveyed 400 primary care doctors and endocrinologists in the United States. The physicians were asked to evaluate 42 real-life circumstances for clients with type two diabetes.

Of the physicians surveyed in the research study, 78 percent stated they were extremely or incredibly likely to buy the PromarkerD test for their type 2 diabetes patients, with just two percent indicating they would not purchase the test.

Proteomics International Managing Director Richard Lipscombe said the publication supplied essential peer-reviewed validation of its preliminary results.

“The professional web-based clinical utility study reveals PromarkerD results ranked as more crucial to doctors than current standard-of-care tests eGFR and ACR,” Dr Lipscombe said.

The published study will form a crucial element of the dossier supporting a United States PLA code reimbursement application for the test.

PromarkerD is a blood test that can anticipate diabetic kidney disease before scientific signs even appear, allowing medical professionals to enhance outcomes for patients with type 2 diabetes while preventing unnecessary interventions for individuals at low threat.

READ  Artificial intelligence and implementation of cancer research